Actualités dans le traitement néoadjuvant du cancer du pancréas (notice n° 666404)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03773cam a2200481 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121194219.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Williet, Nicolas |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Actualités dans le traitement néoadjuvant du cancer du pancréas |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 71 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Pancreatic adenocarcinoma is a growing cause of cancer mortality. Most cases are diagnosed late, with only around 20% of tumors being resectable, borderline or locally advanced and potentially resectable. Tumors are classically classified according to anatomical criteria. Since 2019, however, biological and clinical criteria have been added (A, B and C classification). Neoadjuvant treatment, based essentially on chemotherapy including FOLFIRINOX, aims to improve the chances of complete resection (R0), to treat micrometastases early and to better select the patients for surgery. Nevertheless, despite this rationale, and the evolution of practices towards “all neoadjuvant”, it does not seem so clear that this strategy is the best for upfront resectable tumors. In this update, we report on the latest available data on the evaluation of the benefit of neoadjuvant treatment. The definition of tumor resectability will be reviewed, along with the different treatment modalities (type of chemotherapy, radiotherapy, chemoradiotherapy). |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | L’adénocarcinome du pancréas est une cause croissante de mortalité par cancer. La plupart des cas sont diagnostiqués tardivement, avec seulement environ 20 % des tumeurs résécables d’emblée, de résécabilité limite (« borderline ») ou localement avancées potentiellement résécables. La classification des tumeurs se fait classiquement sur des critères anatomiques, mais depuis 2019 s’y ajoutent des critères biologiques et cliniques (classification A, B et C). Le traitement néoadjuvant, basé essentiellement sur la chimiothérapie, dont le FOLFIRINOX, vise à améliorer les chances de résection complète (R0), à traiter les micro-métastases précocement et à mieux sélectionner les patients à la chirurgie. Néanmoins, malgré ce rationnel, et l’évolution des pratiques vers le « tout néoadjuvant », il n’apparaît pas si clair que cette stratégie soit la meilleure pour les tumeurs résécables d’emblée. Dans cette mise au point, nous rapportons les dernières données disponibles sur l’évaluation du bénéfice du traitement néoadjuvant. La définition de la résécabilité de la tumeur sera revue, ainsi que les différentes modalités de traitement (type de chimiothérapie, radiothérapie et chimio-radiothérapie). |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | traitement néoadjuvant |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | radiothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer du pancréas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chimiothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | traitement néoadjuvant |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | radiothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer du pancréas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chimiothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | traitement néoadjuvant |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | radiothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer du pancréas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chimiothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pancreatic cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | radiotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neoadjuvant treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chemotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pancreatic cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | radiotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neoadjuvant treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chemotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pancreatic cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | radiotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neoadjuvant treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chemotherapy |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | de Mestier, Louis |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Chanez, Brice |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 31 | N° Supp 4 | 2024-09-02 | p. 31-37 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2024-HS4-page-31?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2024-HS4-page-31?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux